The accuracy of Japanese administrative data in identifying acute exacerbation of idiopathic pulmonary fibrosis

Running title: Japanese administrative data in AE-IPF identification

Keisuke Anan^{1,2,3}, Yuki Kataoka^{1,3,4}, Kazuya Ichikado², Kodai Kawamura², Takeshi Johkoh⁵, Kiminori Fujimoto⁶, Kazunori Tobino⁷, Ryo Tachikawa⁸, Hiroyuki Ito⁹, Takahito Nakamura¹⁰, Tomoo Kishaba¹¹, Minoru Inomata¹², Yosuke Yamamoto^{1*}

¹Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan

²Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan

³Systematic Review Workshop Peer Support Group (SRWS-PSG), Osaka, Japan

⁴Department of Internal Medicine, Kyoto Min-Iren Asukai Hospital, Kyoto, Japan

⁵Department of Radiology, Kansai Rosai Hospital, Hyogo, Japan

⁶Department of Radiology, Kurume University School of Medicine, Fukuoka, Japan

⁷Department of Respiratory Medicine, Iizuka Hospital, Fukuoka, Japan

⁸Department of Respiratory Medicine, Kobe City Medical Center General Hospital,
Hyogo, Japan

⁹Department of Pulmonology, Kameda Medical Center, Chiba, Japan

¹⁰Department of Internal Medicine, Nara Prefecture Seiwa Medical Center, Nara, Japan

¹¹Department of Respiratory Medicine, Okinawa Chubu Hospital, Okinawa, Japan

¹²Department of Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo,
Japan

*Corresponding author

Yosuke Yamamoto, M.D., Ph.D.

Department of Healthcare Epidemiology, School of Public Health in the Graduate

School of Medicine, Kyoto University

Yoshida Konoe-cho Sakyo-ku; Kyoto-City 606-8501, Japan

Tel.: +81-75-753-4646

Fax: +81-75-753-4644

Email: yamamoto.yosuke.5n@kyoto-u.ac.jp

Keywords: Idiopathic pulmonary fibrosis, Acute exacerbation, Validation,

Administrative data

Abstract

Background: This study aimed to develop criteria for identifying patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) from Japanese administrative data and validate the pre-existing criteria.

Methods: This retrospective, multi-center validation study was conducted at eight institutes in Japan to verify the diagnostic accuracy of the disease name for AE-IPF. We used the Japanese Diagnosis Procedure Combination data to identify patients with a disease name that could meet the diagnostic criteria for AE-IPF, who were admitted to the eight institutes from January 2016 to February 2019. As a reference standard, two respiratory physicians performed a chart review to determine whether the patients had a disease that met the diagnostic criteria for AE-IPF. Furthermore, two radiologists interpreted the chest computed tomography findings of cases considered AE-IPF and confirmed the diagnosis. We calculated the positive predictive value (PPV) for each disease name and its combination.

Results: We included 830 patients; among them, 216 were diagnosed with AE-IPF through the chart review. We combined the groups of disease names and yielded two criteria: the criteria with the highest PPV (0.72 [95% confidence interval 0.62 to 0.81])

and that with a slightly less PPV (0.61 [0.53 to 0.68]) but more true positives.

Pre-existing criteria showed a PPV of 0.40 (0.31 to 0.49).

Conclusion: The criteria derived in this study for identifying AE-IPF from Japanese administrative data show a fair PPV. Although these criteria should be carefully interpreted according to the target population, our findings could be utilized in future database studies on AE-IPF.

Background

Idiopathic pulmonary fibrosis (IPF) is a rare disease with a poor prognosis that is characterized by chronic progressive lung fibrosis. Although IPF is rare, it has a worse prognosis than numerous cancer types.[1] Moreover, hospitalization and mortality rates attributable to IPF have increased over recent years, which is suggestive of an increasing burden of this disease on healthcare services worldwide.[2-4] During the disease course, acute exacerbation (AE) may occur at an annual frequency of approximately 5–15%; further, the mortality rate is reported to be approximately 50–60%.[5, 6] Few randomized controlled trials (RCTs) with limited external validity have investigated AE-IPF.[7, 8] Therefore, there is a need for large observational studies on a wider patient population using real-world data to complement RCTs.[9]

However, there have been rare seen large-scale database studies on AE-IPF. This could be attributed to the difficulty in identifying cases. In large-scale database research, case identification is essential, with validation studies being crucial for this purpose. The REporting of studies Conducted using Observational Routinely collected health Data (RECORD) statement mentions that “Any validation studies of the codes or algorithms used to select the population should be referenced.”[10] Regarding AE-IPF,

one validation study has been performed in the US[11]; however, the positive predictive value (PPV) was low (0.62 [95% confidence interval [CI] 0.53 to 0.70]). Additionally, it remains unclear whether the data can be applied in other countries.

This study aimed to develop criteria for identifying patients with AE-IPF, as well as validate the criteria in the previous study, using multi-center chart data in Japan.

Methods

We performed and reported this study in accordance with the reporting guidelines for assessing the quality of validation studies of health administrative data (Table S1).[12]

Settings and patients

This retrospective, multicenter, validation study was conducted to verify the diagnostic accuracy of the disease name for AE-IPF. We performed study in eight Japanese tertiary hospitals: Saiseikai Kumamoto Hospital, Hyogo Prefectural Amagasaki General Medical Center, Iizuka Hospital, Kobe City Medical Center General Hospital, Kameda Medical Center, Hoshigaoka Medical Center, Okinawa Chubu Hospital, and the Japanese Red Cross Medical Center.

We included patients aged ≥ 40 years with a disease name that could meet the diagnostic criteria for AE-IPF (Table 1), who were admitted to the aforementioned eight institutes from January 2016 to February 2019. These criteria were developed in advance by two respiratory specialists. We excluded patients with disease names for secondary interstitial pneumonia, including collagen vascular disease-associated interstitial lung disease and chronic and hypersensitivity pneumonitis, as well as those for malignant neoplasms (Table 2). We did not exclude patients with disease names for malignant neoplasms with the suffixes “post-operation” or “post-radiotherapy”. We ignored all “suspected” disease names.

Regarding disease names, we extracted data from the diagnosis procedure combination (DPC), which was launched at Japanese acute-care hospitals across the country in 2003.[13, 14] The following data were extracted from the DPC: some clinical information (e.g. age, gender, etc.), admission route (e.g. scheduled or emergency admission), diagnoses, surgeries and procedures, medications, outcomes, etc. The patients were recorded with diagnostic names using the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes. The diagnoses included the following six categories: main diagnosis, diagnosis that triggered hospitalization, diagnosis using the most medical resources, diagnosis

using the second most medical resources, comorbidities present at admission, and conditions occurring after admission. One diagnostic name is coded for each main diagnosis, diagnosis that triggered hospitalization, diagnosis using the most medical resources, and diagnosis using the second most medical resources. Meanwhile, up to 10 diagnostic names can be coded for comorbidities present at admission and conditions occurring after admission. Furthermore, in the Japanese DPC data, modifiers can be added to the disease name in ICD-10 (e.g., regions such as left and right, recurrence, acute exacerbation, suspected, etc.).

This study was approved by the Ethics Committee of leading institute of this study (Kyoto University Graduate School and Faculty of Medicine) (Approved Number: R2071) and other committed institutes. The requirement for written informed consent from the participants was waived because of the retrospective design and use of anonymized data.

Reference standard

We confirmed the AE-IPF diagnosis using the following two steps:

- 1) At least two respiratory physicians at each institute reviewed the medical records and chest computed tomography (CT) findings on admission. Subsequently, they

determined whether the patients met the following diagnostic criteria: an official ATS/ERS/JRS/ALAT clinical practice guideline for IPF diagnosis [15] and the international working group diagnostic criteria for AE-IPF.[16] An IPF diagnosis was determined if UIP or probable UIP pattern was observed on HRCT findings, even without surgical lung biopsy (SLB). If SLB was performed, IPF was considered based on specific combinations of HRCT and histopathological patterns following the ATS/ERS/JRS/ALAT clinical practice guidelines.[15] Discrepancies were resolved through discussion or consultation with a third respiratory physician, as appropriate.

2) Two expert chest radiologists interpreted chest CT findings of cases considered to be AE-IPF in 1) and determined whether the patients met the aforementioned two diagnostic criteria. If both radiologists considered that a case was not AE-IPF, it was determined as not AE-IPF. On the other hand, if a case was considered as not as AE-IPF by only one radiologist, the case was determined as AE-IPF.

Multidisciplinary discussion (MDD), which is held for diagnostic decision-making regarding patients with interstitial lung disease who are clinically suspected to have IPF, has been described in the official ATS/ERS/JRS/ALAT clinical practice guideline.[15]

However, MDD is a conditional recommendation that is not widely held in Japanese hospitals. Therefore, we decided not to consider MDD as a diagnostic requirement.

Developing criteria

First, we assessed the diagnostic accuracy of each disease name in the inclusion criteria, with disease names showing high diagnostic accuracy being adopted without modification. Next, we explored combinations of disease names with high diagnostic accuracy for disease names with a high number of true positives. We sought to create two criteria: 1) the criteria with the highest PPV (specificity-maximizing criteria) and 2) criteria with slightly less PPV but more true positives (balanced criteria). Based on previous studies, [11, 17, 18] we excluded disease names of secondary interstitial lung diseases (ILDs) and included those of acute respiratory failure (ARF) (Table 3). Further, we excluded disease names with pneumonia, influenza, and aspiration pneumonia and addition of that of IPF.

External validation of the criteria of a previous study

To compare the PPV with the aforementioned newly developed criteria, we externally validated the criteria of a previous study [11] (pre-existing criteria) using DPC data extracted from the aforementioned eight hospitals. The inclusion criteria were as

follows: 1) age ≥ 50 years; 2) having at least one claim to a specific diagnostic code for IPF (either ICD10 code J84.9, J84.10, J84.111, J84.112, or ICD-9 correspond); 3) having acute respiratory symptoms or ARF (J84.114, J84.9, J96.00-02, J96.20-22, J96.91-92, or ICD-9 correspond) and subsequent hospital admission; and 4) lacking secondary ILDs.[11] In accordance with the Japanese DPC data used in this study, we modified this criteria as follows: 1) age ≥ 50 years; 2) having at least one following disease name (either ICD10 code J84.9 [interstitial pneumonia (IP)] or J84.1 [IPF or idiopathic interstitial pneumonia (IIP) or pulmonary fibrosis] in three diagnosis categories (main diagnosis, diagnosis that triggered hospitalization, diagnosis using the most medical resources); 3) having at least one following disease names (ICD10 code J84.1 [acute interstitial pneumonia] or J96.0 [ARF]) in any diagnosis category, and emergency admission; and 4) lacking secondary ILDs.

Statistical analysis

Interobserver agreement for the AE-IPF diagnosis between both respiratory specialists was evaluated using kappa statistics. For cases diagnosed as AE-IPF by two respiratory physicians, the interobserver agreement for AE-IPF diagnosis between both radiologists was assessed using the AC_1 -index since most cases were considered to be true positive

cases.[19] We calculated the PPV as true positives / (true positives + false positives) for every disease name and their combinations. Further, we calculated the 95% confidence intervals (CIs) for binomial distribution using the exact method. We could not calculate the sensitivity, specificity, and negative predictive values since we did not perform a chart review of patients without target ICD-10 codes. Validation studies for only obtaining a PPV have reported that a sample size of approximately 100 is sufficient.[20] We sought to identify patients from various disease names and search for algorithms that would improve PPV. Therefore, regarding the specificity-maximizing criteria, we identified the final criteria with the largest PPV out of approximately 100 cases. Statistical analyses were performed using STATA/SE version.16.0 (Stata Corp., College Station, TX, USA).

Results

This study included 822 patients; among them, 212 were diagnosed with AE-IPF by chart review. There was substantial interobserver agreement for AE-IPF diagnosis (kappa = 0.80 [0.75 to 0.85]). Among the patients who were considered to have AE-IPF by both respiratory physicians, none were considered not to have AE-IPF by both

radiologists; moreover, there was excellent interobserver agreement between both radiologists (AC_1 -index = 0.99 [0.98 to 1]).

Table 4 shows the PPV and 95% CI for each disease name. Although the disease name of AE-IPF and acute exacerbation of IIP (AE-IIP) had the highest and second-highest PPV, respectively, the number of patients was small. The PPV for all the other disease names was low.

Specificity-maximizing criteria

We explored algorithms that would result in higher PPV for the five disease names (AE-IIP, acute exacerbation of interstitial pneumonia, AE-IP, IPF + emergency admission, IIP + emergency admission, and IP + emergency admission) and had more true positive patients. We attempted to exclude disease names related to secondary ILDs and infection, and add to disease names for ARF and IPF. Consequently, we observed an increased PPV for several combinations of disease names.

Finally, we combined the groups of disease names with a higher PPV and yielded a criteria (AE-IPF OR (AE-IIP - secondary ILDs - infection) OR (AE-IIP + IPF) OR (AE-IP - secondary ILDs - infection + ARF) with a PPV of 0.72 (95% CI 0.62 to 0.81) (Table 4).

Balanced criteria

Using the five disease names, we searched for a criteria that would include more true-positive patients even with a slightly inferior PPV. Finally, we created a criteria (AE-IPF OR AE-IIP OR [AE-IP - secondary ILDs + ARF] OR [IPF + emergency admission + [ARF OR AE-IP] OR [IIP + emergency admission + (ARF OR AE-IP)] with a PPV of 0.61 (95% CI 0.53 to 0.68) (Table 4).

Pre-existing criteria

The validation results for the pre-existing criteria (IPF OR IIP OR pulmonary fibrosis OR IP) + (AIP OR ARF) + emergency admissions - secondary ILDs) showed a PPV of 0.40 (95% CI 0.31 to 0.49) (Table 4).

Discussion

Using Japanese administrative data, we created criteria for identifying patients with AE-IPF and validated the pre-existing criteria. It was difficult to accurately identify true positive AE-IPF cases only based on a single disease name. Consequently, we excluded or added various other disease names and emergency admissions, which improved the AE-IPF diagnosis accuracy. The pre-existing criteria had a very low PPV. The PPV for

the final criteria were as follows: specificity-maximizing criteria, 0.72 (0.62 to 0.81); balanced criteria, 0.61 (0.53 to 0.68); and pre-existing criteria, 0.40 (0.31 to 0.49).

The diagnostic accuracy of the specificity-maximizing and balanced criteria showed a fair PPV. Currently, the only validation study on AE-IPF derived a criteria with a PPV of 0.62 (95% CI 0.53 to 0.70),[11] which was lower and comparable to the PPV of the specificity-maximizing and balanced criteria, respectively. Most disease name combinations in the specificity-maximizing criteria used the suffix acute exacerbation, which is unique to the DPC data and may have attributed to the higher PPV compared with that in the previous study. Meanwhile, the validation results for the pre-existing criteria revealed a very low PPV (0.40 [95% CI 0.31 to 0.49]). This indicates that it may be better to use the specificity-maximizing or balanced criteria rather than the pre-existing criteria in the Japanese DPC data.

Meanwhile, our findings are suggestive of the difficulty of AE-IPF diagnosis only based on administrative data. As shown in Table 4, there were only four true-positive patients with a disease name of AE-IPF. IPF is a rare disease; moreover, its diagnosis is heavily dependent on high-resolution CT (HRCT). Additionally, IPF diagnosis is sometimes difficult since it requires the exclusion of all other diseases that

cause chronic fibrosis of the lungs. Furthermore, in case of acute respiratory worsening in fibrotic ILDs, [21] it can be challenging for clinicians to distinguish between AE and others. Therefore, it is very difficult to accurately diagnose AE-IPF; moreover, many true positive patients could have been included among those with disease names of IIP or IP as well as IPF with or without AE. To exclude secondary ILDs, we referred to the ICD-9 and 10 codes used in previous IPF database studies.[11, 17, 18] For AE, we referred to a previous study and added a code for ARF.[11] Combining these codes with IIP and IP increased the PPV; therefore, these codes may be useful for excluding secondary ILDs and including AEs. For diseases that are rare and difficult to diagnose, a PPV of approximately $\geq 70\%$ is considered reasonable [22, 23]. Therefore, given the aforementioned difficulties in diagnosing AE-IPF, the PPVs obtained in our study could be considered reasonable.

Clinical implications

We believe our findings regarding the criteria for identifying patients with AE-IPF can contribute to database research in Japan. Meanwhile, using the specificity-maximizing criteria, only about 1/3 of the cases were true positives. To detect more patients with AE-IPF, it may be better to use the balanced criteria even though it has a lower PPV.

Additionally, the specificity-maximizing and balanced criteria are both insufficient for selecting patients with AE-IPF patients without omission. It should be recognized that some patients with disease names, including acute respiratory distress syndrome or drug-induced interstitial pneumonia, may meet the criteria for AE-IPF. Furthermore, the institutions involved in this study were tertiary hospitals that treat numerous patients with AE-IPF. Although DPC data are collected from numerous acute care hospitals, there were not all proficient in treating patients with AE-IPF; thus, our findings may not be generalizable as representative data for Japan.

Research implication

We created criteria for defining AE-IPF with a fair PPV, however, it was not high. Although the present study and a previous validation study were conducted only using disease names and hospitalization information, an algorithm with a higher PPV can be employed by adding other information, including blood test and prescription data. Additionally, using PPV alone cannot allow for a database study that covers the entire AE-IPF population. Therefore, there is a need for studies calculating the sensitivity and specificity using methods, including random sampling or "all possible cases" sampling.[24]

Strength and Limitations

Our study has several strengths. First, this is the first validation study on AE-IPF using Japanese DPC data. Second, this was a multi-center study with a sufficient sample size. Third, AE-IPF diagnosis was more reliable because of the interpretation by two chest radiologists in addition to at least two pulmonologists.

This study had several limitations. First, since this study was conducted at tertiary emergency hospitals with respiratory specialists, it remains unclear whether it can be adapted to the entire DPC data in Japan. Therefore, our findings should be externally validated in other facilities in Japan. Second, this was a validation study of the Japanese DPC data, which is unique to Japan and does not apply to other countries. Finally, we cannot eliminate the possibility of misclassification of the IPF diagnosis (e.g., hypersensitivity pneumonitis and collagen vascular disease) or AE. However, we believe that this was reduced by the interpretation of the chest CT findings by two expert chest radiologists.

Conclusion

In conclusion, this study derived criteria for identifying AE-IPF from Japanese administrative data with a fair PPV. When studying AE-IPF in Japanese administrative

data using the specificity-maximizing or balanced criteria, researchers should carefully interpret the target population.

Funding

The English editing fee was supported by Saiseikai Kumamoto Hospital. The funder did not play any role in the design of the study and collection, analysis and interpretation of data.

Conflicts of interest

Keisuke Anan received a research grant from Systematic Review Workshop Peer Support Group and Fujiwara Memorial Foundation for other research purposes. Yuki Kataoka received a research grant from the Systematic Review Workshop Peer Support Group, the Japan Osteoporosis Foundation, and Yasuda Memorial Medical Foundation for other research purposes.

Acknowledgments

We are grateful to Asuka Iwashita (Saiseikai Kumamoto Hospital), Hiromi Ide (Iizuka Hospital), Keiko Sakuragawa (Kobe City Medical Center General Hospital), Kyoko Wasai (Hyogo Prefectural Amagasaki General Medical Center), Hiroshi Harada (Kameda Medical Center), Megumi Kunita (Hoshigaoka Medical Center), Daiki Chinen (Okinawa Chubu Hospital), and Misao Ebihara (Japanese Red Cross Medical Center) for retrieving data. We would like to thank Editage (www.editage.com) for English language editing.

References

1. du Bois RM. An earlier and more confident diagnosis of idiopathic pulmonary fibrosis. *Eur Respir Rev* 2012;21:141–6.
2. Hutchinson J, Fogarty A, Hubbard R, McKeever T. Global incidence and mortality of idiopathic pulmonary fibrosis: A systematic review. *Eur Respir J* 2015;46:795–806.

3. Hutchinson JP, McKeever TM, Fogarty AW, Navaratnam V, Hubbard RB.

Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century. *Ann Am Thorac Soc* 2014;11:1176–85.
4. Navaratnam V, Fogarty AW, Glendening R, McKeever T, Hubbard RB. The

increasing secondary care burden of idiopathic pulmonary fibrosis: hospital admission trends in England from 1998 to 2010. *Chest* 2013;143:1078–84.
5. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al.

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med* 2014;370:2071–82.
6. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of

idiopathic pulmonary fibrosis: incidence, risk factors and outcome. *Eur Respir J* 2011;37:356–63.
7. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An

official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med* 2011;183:788–824.

8. Homma S, Bando M, Azuma A, Sakamoto S, Sugino K, Ishii Y, et al. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. *Respir Investig* 2018;56:268–91.
9. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. *J Clin Epidemiol* 2005;58:323–37.
10. Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. *PLoS Med* 2015;12:e1001885.
11. Farrand E, Vittinghoff E, Ley B, Butte AJ, Collard HR. Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF. *Respirology* 2020;25:629–35.
12. Benchimol EI, Manuel DG, To T, Griffiths AM, Rabeneck L, Guttman A. Development and use of reporting guidelines for assessing the quality of validation studies of health administrative data. *J Clin Epidemiol* 2011;64:821–9.
13. Okamura S, Kobayashi R, Sakamaki T. Case-mix payment in Japanese medical care. *Health Policy* 2005;74:282–6.

14. Yasunaga H, Ide H, Imamura T, Ohe K. Impact of the Japanese Diagnosis Procedure Combination-based Payment System on cardiovascular medicine-related costs. *Int Heart J* 2005;46:855–66.
15. Raghu G, Jardin MR, Myers JL, Richeldi L, Ryerson CL, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med* 2018;198:e44–e68.
16. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. *Am J Respir Crit Care Med* 2016;194:265–75.
17. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2006;174:810–6.
18. Lai CC, Wang CY, Lu HM, Chen L, Teng NC, Yan YH, et al., Idiopathic pulmonary fibrosis in Taiwan - A population-based study. *Respir Med* 2012;106:1566–74.

19. Shankar V, Bangdiwala SI. Observer agreement paradoxes in 2x2 tables: Comparison of agreement measures. *BMC Med Res Methodol* 2014;14:100.
20. Cutrona SL, Toh S, Iyer A, Foy S, Cavagnaro E, Forrow S et al., Design for validation of acute myocardial infarction cases in Mini-Sentinel. *Pharmacoepidemiol Drug Saf* 2012;21:274–81.
21. Moua T, Westerly BD, Dulohery MM, Daniels CE, Ryu JH, Lim KG. Patients with fibrotic interstitial lung disease hospitalized for acute respiratory worsening: A large cohort analysis. *Chest* 2016;149:1205–14.
22. Segal JB, Powe NR. Accuracy of identification of patients with immune thrombocytopenic purpura through administrative records: A data validation study. *Am J Hematol* 2004;75:12–7.
23. Wahl PM, Terrell DR, George JN, Rodgers JK, Uhl L, Cataland S, et al. Validation of claims-based diagnostic codes for idiopathic thrombotic thrombocytopenic purpura in a commercially-insured population. *Thromb Haemost* 2010;103:1203–9.

24. Widdifield J, Ivers NM, Young J, Green D, Jaakkimainen L, Butt DA, et al.
Development and validation of an administrative data algorithm to estimate the disease
burden and epidemiology of multiple sclerosis in Ontario, Canada. *Mult Scler*
2015;21:1045–54.

Table 1

Disease names adopted as inclusion criteria

ICD-10 code 1	disease name 1*	suffix	ICD-10 code 2	disease name 2**	suffix	emergency admission
J841	idiopathic pulmonary fibrosis	AE	-	-	-	-
J841	idiopathic interstitial pneumonia	AE	-	-	-	-
J841	usual interstitial pneumonia	AE	-	-	-	-
J841	pulmonary fibrosis	AE	-	-	-	-
J841	diffuse interstitial pneumonia	AE	-	-	-	-
J849	interstitial pneumonia	AE	-	-	-	-
J841	acute interstitial pneumonia	-	-	-	-	-
J841	diffuse interstitial pneumonia	-	-	-	-	-
J841	diffuse alveolar damage	-	-	-	-	-
J80	acute respiratory distress syndrome	-	-	-	-	-
J984	acute lung injury	-	-	-	-	-
J702	acute drug-induced interstitial lung disorders	-	-	-	-	-
J704	drug-induced interstitial pneumonia	-	-	-	-	-
J10~J111 J15~189 J690	pneumonia, Influenza, aspiration pneumonia	-	J841	idiopathic pulmonary fibrosis	AE	-
		-	J841	idiopathic interstitial pneumonia	AE	-
		-	J841	usual interstitial pneumonia	AE	-
		-	J841	pulmonary fibrosis	AE	-
		-	J841	diffuse interstitial pneumonia	AE	-
		-	J841	interstitial pneumonia	AE	-
		-	J841	idiopathic pulmonary fibrosis	-	-

		-	J841	idiopathic interstitial pneumonia	-	-
		-	J841	usual interstitial pneumonia	-	-
		-	J841	pulmonary fibrosis	-	-
		-	J841	diffuse interstitial pneumonia	-	-
		-	J841	interstitial pneumonia	-	-
J841	idiopathic pulmonary fibrosis	-	-	-	-	○
J841	idiopathic interstitial pneumonia	-	-	-	-	○
J841	usual interstitial pneumonia	-	-	-	-	○
J841	pulmonary fibrosis	-	-	-	-	○
J841	diffuse interstitial pneumonia	-	-	-	-	○
J849	interstitial pneumonia	-	-	-	-	○

AE, acute exacerbation; DPC, diagnosis procedure combination; ICD-10, the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision

*Disease name in any categories in the DPC data

**Disease name in co-morbidities present at admission and conditions occurring after admission

Table 2

Disease names adopted as exclusion criteria

ICD-10 code	disease name*
C00~C96	malignant neoplasms**
D860	sarcoidosis of lung
J60	coal worker's pneumoconiosis
J61	asbestosis
J64	pneumoconiosis
J67	hypersensitivity pneumonitis due to organic dust
J990 · M0510	rheumatoid arthritis-associated interstitial lung disease
J991 · M351	collagen vascular disease-associated interstitial lung disease
J991 · M330	juvenile dermatomyositis-associated interstitial lung disease
J991 · M321	systemic lupus erythematosus-associated interstitial lung disease
J991 · M332	polymyositis-associated interstitial lung disease
J991 · M331	dermatomyositis-associated interstitial lung disease
J991 · M313	lung involvement in granulomatosis with polyangiitis
M348	lung involvement in systemic sclerosis

* Disease name in any category in the DPC data

**not exclude if they have attached suffix of “post-operation” or “post-radiotherapy”.

Table 3

ICD-10 codes for interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) and acute respiratory failure.

ILDs other than IPF	
ICD-10 code	disease name
C966	Langerhans-cell histiocytosis*
D869	Sarcoidosis
E756	Lipidoses
J998 • E831	Idiopathic pulmonary hemosiderosis
E85	Amyloidosis
J60	coal worker's pneumoconiosis*
J61	asbestosis*
J62	silicosis or talcosis
J63	berylliosis and other inorganic dusts
J64	unspecified pneumoconiosis*
J67	hypersensitivity pneumonitis*
J82	Pulmonary eosinophilia, not elsewhere classified
J82	Extrinsic allergic alveolitis
J684	Chronic respiratory conditions due to chemicals, gases, fumes, and vapors
J701	Chronic and other pulmonary manifestations due to radiation
J708	Respiratory conditions due to other specified external agents
J840	Alveolar and parieto-alveolar conditions
J841	Postinflammatory pulmonary fibrosis
J99	Respiratory disorders in diseases classified elsewhere
K50	Regional enteritis
M05, M06	Rheumatoid arthritis
M310	Goodpasture' s syndrome
M313	Wegener' s granulomatosis
M317	Microscopic polyangiitis
M318	Other specified necrotizing vasculopathies
M321, M329	Systemic lupus erythematosus
M330, M331, M339	Dermatomyositis
M332	Polymyositis
M340, M341, M349	Systemic sclerosis
M348	Lung involvement in systemic sclerosis*
M350	Sjogren' s disease
M351	other overlap syndrome

M45	Ankylosing spondylitis
Q850	Neurofibromatosis
Q851	Tuberous sclerosis
Acute respiratory failure	
ICD-10 code	disease name
J960	acute respiratory failure

*We already excluded these disease names as exclusion criteria

Table 4

The positive predictive value (PPV) and 95% confidence intervals (CI) of patients diagnosed with acute exacerbation of idiopathic pulmonary fibrosis within each algorithm

disease names	total (n)	True Positives	PPV	95% CI
IPF + AE	5	4	0.8	0.28 to 0.99
IIP + AE	32	24	0.75	0.57 to 0.89
(IIP + AE) - secondary ILDs*	30	23	0.77	0.58 to 0.90
(IIP + AE) - secondary ILDs + ARF*	22	17	0.77	0.55 to 0.92
(IIP + AE) - secondary ILDs - infection	29	22	0.76	0.55 to 0.92
(IIP + AE) - secondary ILDs - infection + ARF	21	16	0.76	0.56 to 0.90
(IIP + AE) + IPF	6	6	1	0.54 to 1
UIP + AE	0	0	-	-
pulmonary fibrosis + AE	2	1	0.5	0.13 to 0.99
diffuse IP + AE	8	1	0.13	0.003 to 0.53
IP + AE	105	59	0.56	0.46 to 0.66
(IP + AE) - secondary ILDs	95	57	0.6	0.49 to 0.70
(IP + AE) - secondary ILDs + ARF	75	50	0.67	0.55 to 0.77
(IP + AE) - secondary ILDs - infection	77	48	0.62	0.51 to 0.73
(IP + AE) - secondary ILDs - infection + ARF	60	42	0.7	0.57 to 0.81
(IP + AE) + IPF	15	9	0.6	0.32 to 0.84
(IP + AE) + IPF - secondary ILDs - infection	12	8	0.67	0.35 to 0.90
AIP	40	11	0.28	0.15 to 0.44
diffuse IP	86	8	0.093	0.041 to 0.18
DAD	1	0	0	0 to 0.98
ARDS	66	5	0.076	0.025 to 0.17
ALI	2	0	0	0 to 0.84

acute drug-induced interstitial lung disorders	13	1	0.077	0.002 to 0.36
drug-induced interstitial pneumonia	47	2	0.043	0.005 to 0.15
Infection + (IPF + AE)	0	0	-	-
Infection + (IIP + AE)	1	0	0	0 to 0.98
Infection + (UIP + AE)	0	0	-	-
Infection + (pulmonary fibrosis + AE)	0	0	-	-
Infection + (diffuse IP+AE)	0	0	-	-
Infection + (IP + AE)	11	4	0.36	0.11 to 0.69
Infection + IPF	15	3	0.2	0.043 to 0.48
Infection + IIP	15	3	0.2	0.043 to 0.48
Infection + UIP	0	0	-	-
Infection + pulmonary fibrosis	5	0	0	0 to 0.52
Infection + diffuse IP	3	0	0	0 to 0.71
Infection + IP	82	11	0.13	0.069 to 0.23
IPF + emergency admission	40	16	0.4	0.25 to 0.57
IPF + emergency admission + ARF	15	10	0.67	0.38 to 0.88
IPF + emergency admission - secondary ILDs - infection + ARF	12	8	0.67	0.35 to 0.90
IPF + emergency admission + (IP + AE)	4	2	0.5	0.068 to 0.93
IIP + emergency admission	152	35	0.23	0.17 to 0.31
IIP + emergency admission + ARF	47	19	0.40	0.26 to 0.56
IIP + emergency admission - secondary ILDs - infection + ARF	21	7	0.33	0.15 to 0.57
IIP + emergency admission + (IP + AE)	3	2	0.67	0.094 to 0.99
UIP + emergency admission	11	4	0.36	0.11 to 0.69
pulmonary fibrosis + emergency admission	3	0	0	0 to 0.71
diffuse IP + emergency admission	53	7	0.13	0.055 to 0.25
IP + emergency admission	140	38	0.27	0.20 to 0.35

IP + emergency admission + ARF	78	27	0.35	0.24 to 0.46
IP + emergency admission - secondary ILDs - infection + ARF	45	14	0.31	0.18 to 0.47
final algorithm				
Specificity maximizing criterion				
(IPF + AE) OR ((IIP + AE) - secondary ILDs - infection) OR ((IIP + AE) + IPF) OR ((IP + AE) - secondary ILDs - infection + ARF)	94	68	0.72	0.62 to 0.81
Balanced algorithm				
(IPF + AE) OR (IIP + AE) OR ((IP + AE) - secondary ILDs + ARF) OR (IPF + emergency admission + (ARF OR (IP + AE))) OR (IIP + emergency admission + (ARF OR (IP + AE)))	168	102	0.61	0.53 to 0.68
Pre-existing criterion				
((IPF OR IIP OR pulmonary fibrosis OR IP) + (AIP OR ARF) + emergency admission - secondary ILDs)	126	50	0.40	0.31 to 0.49

AE, acute exacerbation; AIP, acute interstitial pneumonia; ALI, acute lung injury; ARDS, acute respiratory distress syndrome; ARF, acute respiratory failure; DAD, diffuse alveolar damage; IIP, idiopathic interstitial pneumonia; ILDs, interstitial lung diseases; IP, interstitial pneumonia; IPF, idiopathic pulmonary fibrosis; UIP, usual interstitial pneumonia

*disease names of secondary ILDs and ARF are described in Table 3

Table S1. Checklist of reporting criteria for studies validating health administrative data algorithms.

	YES	NO	UNCERTAIN	NOT APPLICABLE
TITLE, KEYWORDS, ABSTRACT				
Identify article as study of assessing diagnostic accuracy	✓ ▪			
Identify article as study of administrative data	✓ ▪			
INTRODUCTION:				
State disease identification & validation one of goals of study	✓ ▪			
METHODS:				
<i>Participants in validation cohort:</i>				
Describe validation cohort (Cohort of patients to which reference standard was applied)	✓ ▪			
· Age		✓ ▪		
· Disease	✓ ▪			
· Severity				✓ ▪
· Location/Jurisdiction	✓ ▪			
Describe recruitment procedure of validation cohort	✓ ▪			
· Inclusion criteria	✓ ▪			
· Exclusion criteria	✓ ▪			

Describe patient sampling (random, consecutive, all, etc.)	✓ ▪			
Describe data collection	✓ ▪			
· Who identified patients and did selection adhere to patient recruitment criteria	✓ ▪			
· Who collected data	✓ ▪			
· A <i>priori</i> data collection form	✓ ▪			
· Disease classification				✓ ▪
· Split sample (i.e. re-validation using a separate cohort)				✓ ▪

	YES	NO	UNCERTAIN	NOT APPLICABLE
METHODS (cont.):				
<i>Test Methods:</i>				
Describe number, training and expertise of persons reading reference standard	✓ ▪			
If >1 person reading reference standard, quote measure of consistency (e.g. kappa)	✓ ▪			
Blinding of interpreters of reference standard to results of classification by administrative data e.g. Chart abstractor blinded to how that chart was coded			✓ ▪	
<i>Statistical Methods:</i>				

Describe methods of calculating/comparing diagnostic accuracy	✓ ▪			
RESULTS:				
<i>Participants:</i>				
Report when study done, start/end dates of enrollment	✓ ▪			
Describe number of people who satisfied inclusion/exclusion criteria	✓ ▪			
Study flow diagram				✓ ▪
<i>Test results:</i>				
Report distribution of disease severity				✓ ▪
Report cross-tabulation of index tests by results of reference standard	✓ ▪			

	YES	NO	UNCERTAIN	NOT APPLICABLE
RESULTS (cont.):				
<i>Estimates:</i>				
Report at least 4 estimates of diagnostic accuracy				✓ ▪
Diagnostic Accuracy Measures Reported:	✓ ▪			
· Sensitivity				✓ ▪
· Spec				✓ ▪
· PPV	✓ ▪			

· NPV				✓
· Likelihood ratios				✓
· Kappa	✓			
· Area under the ROC curve / c-statistic				✓
· Accuracy/agreement	✓			
· Other (specify)				✓
Report accuracy for subgroups (e.g. age, geography, different sex, etc.)				✓
If PPV/NPV reported, ratio of cases/controls of validation cohort approximate prevalence of condition in the population			✓	
Report 95% confidence intervals for each diagnostic measure	✓			
DISCUSSION:				
Discuss the applicability of the validation findings	✓			